IDEXX Laboratories, Inc. (NASDAQ:IDXX) currently has an A verage Broker Rating of 2.29. This number is based on the 7 sell-side firms polled by Zacks. The ABR rank within the industry stands at 30. Analysts on a consensus basis are expecting that the stock will reach $159.33 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.
Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares.
Research analysts are predicting that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will report earnings of $0.71 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted quarterly earnings of $0.95 which compared to the sell-side estimates of 0.75. The stock’s 12-month trailing earnings per share stands at $2.8. Shares have moved $0.65 over the past month and more recently, $2.98 over the past week heading into the earnings announcement. There are 4 analyst projections that were taken into consideration from respected brokerage firms.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) closed the last session at $158.97 and sees an average of 428883.31 shares trade hands in each session. The 52-week low of the stock stands at $103.98 while the current level stands at 80.92% of the 52-week High-Low range. Looking further out we can see that the stock has moved -2.82% over the past 12 weeks and 35.56% year to date.
4 analysts rate IDEXX Laboratories, Inc. a Buy or Strong Buy, which is 57.14% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.